Dyne Therapeutics Inc (NASDAQ: DYN) is -48.30% lower on its value in year-to-date trading and has touched a low of $11.62 and a high of $47.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DYN stock was last observed hovering at around $11.89 in the last trading session, with the day’s gains setting it 0.29%.
Currently trading at $12.18, the stock is -12.18% and -27.07% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.53 million and changing 2.44% at the moment leaves the stock -59.76% off its SMA200. DYN registered -58.19% loss for a year compared to 6-month loss of -73.57%.
The stock witnessed a -12.18% gain in the last 1 month and extending the period to 3 months gives it a -60.21%, and is -11.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.30% over the week and 6.91% over the month.
Dyne Therapeutics Inc (DYN) has around 191 employees, a market worth around $1.38B and $0.00M in sales. Distance from 52-week low is 4.82% and -74.33% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.91%).
The EPS is expected to shrink by -6.72% this year
The shares outstanding are 102.32M, and float is at 84.03M with Short Float at 12.97%.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.39 million shares valued at $260.69 million. The investor’s holdings represent 9.1148 of the DYN Shares outstanding. As of 2024-06-30, the second largest holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with 8.02 million shares valued at $283.03 million to account for 8.6697 of the shares outstanding. The other top investors are FCPM III SERVICES B.V. which holds 7.85 million shares representing 8.4808 and valued at over $276.86 million, while RTW INVESTMENTS, LP holds 6.9044 of the shares totaling 6.39 million with a market value of $225.4 million.
Dyne Therapeutics Inc (DYN) Insider Activity
A total of 0 insider transactions have happened at Dyne Therapeutics Inc (DYN) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Still, SEC filings show that on Mar 05 ’25, Beskrovnaya Oxana (Officer) Proposed Sale 1,094 shares at an average price of $11.89 for $13007.0. The insider now directly holds shares of Dyne Therapeutics Inc (DYN).
Dyne Therapeutics Inc (DYN): Who are the competitors?
One of the company’s main competitors (and peers) include Vertex Pharmaceuticals Inc. (VRTX) that is trading 19.37% up over the past 12 months.Biogen Inc. (BIIB) lies in the list of competitors of the Dyne Therapeutics Inc and is -33.92% lower over the same period from DYNSarepta Therapeutics Inc. (SRPT) is -10.51% down on the 1-year trading charts.
